<DOC>
	<DOC>NCT01974687</DOC>
	<brief_summary>This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-3682 (IDX21437) in healthy participants and in participants infected with HCV genotype (GT)1-GT6. The effect of food on the PK of MK-3682 will be evaluated. The antiviral activity of MK-3682 will also be assessed in HCV-infected participants.</brief_summary>
	<brief_title>Single and Multiple Dose Study of MK-3682 (IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>All Participants: of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug must not have consumed grapefruit or grapefruit juice within 7 days of Day 1 and throughout the study HCV Participants: documented clinical history compatible with chronic hepatitis C. have not received directacting antiviral treatment for hepatitis C infection has HCV Genotype 1, 2, 3, 4, 5 or 6 All Participants: pregnant or breastfeeding coinfected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV). decompensated liver disease other clinically significant medical conditions or laboratory abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>